A data-informed innovative pharmaceutical launch

Launching strategically with Gilead Sciences

Combining unique research methods unlocked deep market insights — and the secret to a highly successful pharmaceutical launch in a crowded market

Gilead, an American biopharmaceutical company, called upon Daman’s expertise to stand out from the crowd as they launched their new rheumatoid arthritis (RA) treatment in a highly competitive market. We built a market insight-based launch plan that combined qualitative research with real-world evidence (RWE) data.

The problem
As a small newcomer to the rheumatoid arthritis treatment market with stiff competition from larger, well-established players, Gilead needed a smart and unique launch plan for their innovative RA drug.

The innovation
Combining qualitative research methods with RWE analysis to build a successful launch strategy and unlock deep market insights.

The Daman team conducted interviews and analysis of RWE from anonymized RheumaBuddy data.

The outcome
Daman’s unique approach to integrating qualitative research with RWE data — captured in a 16-page report with images — empowered the driven, passionate and cross-functional team at Gilead to launch their new RA drug in a highly competitive market.